BRAFi and/or MEKi resistance in A375 cell line. Homo sapiens
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
Genetic analysis of A375 cell line resistant to BRAF and/or MEK inhibitors
应用场景：
创建时间：
2019-04-10
相关数据集
Ccr2+ monocyte-derived macrophages influence trajectories of acquired therapy resistance in Braf-mutant melanoma. Ccr2+ monocyte-derived macrophages influence trajectories of acquired therapy resistance in Braf-mutant melanoma
Therapies targeting oncogene addiction have had a tremendous impact on tumor growth and patient outcome, but drug resistance continues to be problematic. One approach to deal with the challenge of res
NIAID Data Ecosystem30
Table_1_Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling.docx
Melanoma, the most threatening cancer in the skin, has been considered to be driven by the carcinogenic RAF-MEK1/2-ERK1/2 signaling pathway. This signaling pathway is usually mainly dysregulated by mu
NIAID Data Ecosystem10
Acquired resistance to MEK-CDK4/6 inhibitor combinations in cutaneous melanoma
Continuous MEK and CDK4/6 inhibition is effective in pre-clinical models, nevertheless, some tumors acquire resistance that was associated with enhanced phospho S6. To characterize the mechanism media
NIAID Data Ecosystem30
Anti-proliferative effects of continued mitogen activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma: Implications for treatment beyond disease progression
Anti-proliferative effects of continued mitogen activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma: Implications for treatment beyond d
ChEBI2013-06-30 更新10
